ARK reports 9.95% stake in Beam Therapeutics
Beam Therapeutics Inc. is reported as having a significant shareholder.
Rhea-AI Filing Summary
Beam Therapeutics Inc. is reported as having a significant shareholder. ARK Investment Management LLC and its CEO/CIO Catherine D. Wood report beneficial ownership of 10,234,862 shares of Beam common stock, representing 9.95% of the class as of the reporting date.
ARK has sole voting power over 9,639,107 shares and shared voting power over 151,313 shares, with sole dispositive power over 10,234,862 shares. Catherine D. Wood has shared voting power over 9,790,420 shares and shared dispositive power over 10,234,862 shares. ARK notes that no client currently has more than a 5% interest in these securities except ARK Innovation ETF.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
beneficially owned financial
sole voting power financial
sole dispositive power financial
Schedule 13G regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What voting power does ARK Investment Management have in Beam Therapeutics (BEAM)?
What is Catherine D. Wood’s reported voting and dispositive power in Beam Therapeutics (BEAM)?
Which ARK client holds more than 5% interest in Beam Therapeutics (BEAM) securities?
Who are the reporting persons in the Beam Therapeutics (BEAM) Schedule 13G/A?
AI-generated analysis. How Rhea-AI works. Not financial advice.